| Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development includes FT516 for the treatment of acute myeloid leukemia (AML) and B-cell lymphoma, FT596 to treat B-cell lymphoma and CLL, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT819 to treat B-cell malignancies, and FT-ONO1 to treat hematologic malignancies; and FT500, FT516, and FT-ONO2 for the treatment of advanced solid tumors. The company's NK- and T-cell immuno-oncology programs under development also includes ProTmune for the treatment of hematologic malignancies; FATE-NK100 for the treatment of recurrent ovarian cancer; and FATE-NK100 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Redmile Group, LLC | Director | Jun 11 | Buy | 28.31 | 1,412,928 | 39,999,992 | 12,629,737 | Jun 17 08:25 PM | | RASTETTER WILLIAM H | Director | Mar 30 | Option Exercise | 1.37 | 28,461 | 38,992 | 28,461 | Mar 31 04:01 PM | | Valamehr Bahram | Chief Development Officer | Feb 03 | Option Exercise | 1.69 | 1,153 | 1,949 | 87,211 | Feb 04 04:01 PM | | Wolchko J Scott | President and CEO | Jan 30 | Option Exercise | 2.70 | 25,000 | 67,500 | 444,969 | Feb 03 04:01 PM | | Wolchko J Scott | President and CEO | Jan 30 | Sale | 25.45 | 25,000 | 636,303 | 419,969 | Feb 03 04:01 PM | | Valamehr Bahram | Chief Development Officer | Jan 08 | Sale | 20.69 | 5,700 | 117,947 | 86,058 | Jan 10 04:03 PM | | TAHL CINDY | General Counsel and Secretary | Jan 08 | Sale | 20.72 | 5,700 | 118,085 | 99,518 | Jan 10 04:02 PM | | Shoemaker Daniel D | Chief Scientific Officer | Jan 08 | Sale | 20.70 | 5,700 | 117,986 | 143,091 | Jan 10 04:01 PM | | Shoemaker Daniel D | Chief Scientific Officer | Dec 30 | Option Exercise | 2.90 | 25,000 | 72,500 | 148,791 | Jan 02 04:01 PM | | Shoemaker Daniel D | Chief Scientific Officer | Dec 30 | Sale | 19.50 | 25,000 | 487,427 | 123,791 | Jan 02 04:01 PM | | Wolchko J Scott | President and CEO | Dec 20 | Option Exercise | 2.70 | 25,000 | 67,500 | 378,969 | Dec 23 04:02 PM | | Wolchko J Scott | President and CEO | Dec 20 | Sale | 20.17 | 25,000 | 504,158 | 353,969 | Dec 23 04:02 PM | | Wolchko J Scott | President and CEO | Dec 19 | Option Exercise | 2.70 | 25,000 | 67,500 | 378,969 | Dec 23 04:02 PM | | Wolchko J Scott | President and CEO | Dec 19 | Sale | 20.08 | 25,000 | 501,898 | 353,969 | Dec 23 04:02 PM | | Valamehr Bahram | Chief Development Officer | Oct 15 | Sale | 14.18 | 6,200 | 87,891 | 66,758 | Oct 16 04:06 PM | | Wolchko J Scott | President and CEO | Oct 15 | Sale | 14.44 | 21,017 | 303,458 | 353,969 | Oct 16 04:07 PM | | TAHL CINDY | General Counsel and Secretary | Oct 15 | Sale | 14.24 | 10,200 | 145,292 | 80,218 | Oct 16 04:05 PM | | Shoemaker Daniel D | Chief Scientific Officer | Oct 15 | Sale | 14.29 | 11,800 | 168,593 | 123,791 | Oct 16 04:04 PM | | Redmile Group, LLC | Director | Sep 16 | Buy | 17.50 | 857,143 | 15,000,003 | 11,216,809 | Sep 17 04:22 PM | | Nashat Amir | Director | Aug 01 | Sale | 22.53 | 30,866 | 695,392 | 7,539 | Aug 02 04:32 PM | | Nashat Amir | Director | Jul 31 | Sale | 22.53 | 31,139 | 701,674 | 7,743 | Aug 02 04:32 PM | | Nashat Amir | Director | Jul 30 | Sale | 22.51 | 90,175 | 2,029,560 | 7,949 | Jul 30 06:25 PM | | Nashat Amir | Director | Jul 29 | Sale | 22.50 | 329 | 7,403 | 8,545 | Jul 30 06:25 PM | | Nashat Amir | Director | Jul 26 | Sale | 22.50 | 27,829 | 626,153 | 8,548 | Jul 30 06:25 PM | | Nashat Amir | Director | Jul 24 | Sale | 22.51 | 19,866 | 447,098 | 8,732 | Jul 25 06:24 PM | | Nashat Amir | Director | Jul 23 | Sale | 22.51 | 62,033 | 1,396,053 | 8,864 | Jul 25 06:24 PM | | Nashat Amir | Director | Jul 22 | Sale | 22.52 | 48,704 | 1,097,019 | 9,275 | Jul 22 05:52 PM | | Nashat Amir | Director | Jul 19 | Sale | 22.50 | 1,053 | 23,693 | 9,598 | Jul 22 05:52 PM | | Nashat Amir | Director | Jul 18 | Sale | 22.50 | 21,409 | 481,795 | 9,605 | Jul 22 05:52 PM |
|
